Lymphoma & CLL Subtypes

Mosunetuzumab in heavily pretreated follicular lymphoma: Phase I dose-escalation trial updates

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub...

What factors should be considered when sequencing therapy in R/R follicular lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to...

Acalabrutinib meets primary endpoint in ELEVATE-RR trial for patients with R/R CLL

On January 25, 2021, it was announced that acalabrutinib has met its primary endpoint of non-inferior...

5-year results of the MURANO phase III trial of venetoclax + rituximab vs bendamustine + rituximab in patients with CLL

During the 62nd American Society of Hematology (ASH) Annual Meeting and...

CFT7455 receives clearance of Investigational New Drug Application by FDA for the treatment of multiple myeloma and non-Hodgkin lymphoma

The U.S. Food and Drug Administration (FDA) announced the...

What novel therapies are showing promise for patients with heavily pretreated MCL?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke to Michael...

How effective is nivolumab + brentuximab vedotin as a consolidation therapy for Hodgkin lymphoma?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub...

EMA grants PRIME designation to anti-CD30 CAR-T cell therapy for the treatment of patients with R/R cHL

On January 18, 2021, it was announced that the European Medicines Agency (EMA) granted Priority...